Vimarsana
Biggest News Aggregation in the World

Page 3 - Johnson Rybrevant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Johnson Rybrevant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Johnson Rybrevant Today - Breaking & Trending Today

BioPharma Marketing News | BioPharma Dive - Vimarsana News

BioPharma Marketing News | BioPharma Dive

The latest news in marketing in the biotech and biopharmaceutical industry.

Tentarix Bio unveils $50M for biologics with multiple functions, multiple targets - Vimarsana News

Tentarix Bio unveils $50M for biologics with multiple functions, multiple targets

Biotech startup Tentarix Biotherapeutics has come out of stealth with $50 million and technology that develops biologic drugs endowed with multiple functions. The company aims to develop new multispecific biologic drugs for cancer and autoimmune diseases.

J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies - Vimarsana News

J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies

*in combination with other drugs **enrollment paused SOURCE: Company disclosures, clinicaltrials.gov In multiple myeloma, many companies are taking aim at a disease-specific protein called BCMA, following the same approach of the approved drugs Blenrep from GlaxoSmithKline and Abecma from Bristol Myers Squibb. In leukemia and lymphoma, the target protein on the tumor cells is called CD20, to which the aging Roche drug Rituxan also binds. Roche is the most advanced using the CD20/CD3 approach, with two drugs called mosunetuzumab and glofitamab in Phase 3 trials. The former is being tested in c...